TY - JOUR T1 - The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment. AU - Çınarka,Halit, AU - Günlüoğlu,Gülşah, AU - Çörtük,Mustafa, AU - Yurt,Sibel, AU - Kıyık,Murat, AU - Koşar,Filiz, AU - Tanrıverdi,Elif, AU - Arslan,Melih Akay, AU - Baydili,Kürşad Nuri, AU - Koç,Aysu Sinem, AU - Altın,Sedat, AU - Çetinkaya,Erdoğan, Y1 - 2021/08/30/ PY - 2020/12/15/received PY - 2021/3/14/accepted PY - 2021/3/17/entrez PY - 2021/3/18/pubmed PY - 2021/9/15/medline KW - COVID-19 KW - favipravir KW - lopinavir/ritonavir KW - mortality KW - pneumonia SP - 1624 EP - 1630 JF - Turkish journal of medical sciences JO - Turk J Med Sci VL - 51 IS - 4 N2 - BACKGROUND/AIM: SARS-CoV-2, a ribonucleic acid coronavirus, rapidly spread worldwide within a short timeframe. Although different antiviral, antiinflammatory, and immunomodulatory drugs are used, current evidence is insufficient as to which drug is more efficient. Our study compared favipiravir and lopinavir/ritonavir (LPV/RTV) therapies in inpatient care for coronavirus disease 2019 (COVID-19) pneumonia. MATERIALS AND METHODS: Demographic data, test results, treatments, and latest status of patients receiving inpatient COVID-19 pneumonia therapy were recorded. The initial favipiravir and LPV/RTV receiving groups were compared regarding the need for intensive care units (ICU) and mortality. Logistic regression analysis was performed by including variables showing significant differences as a result of paired comparisons into the model. RESULTS: Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex, presence of comorbidity, and tocilizumab, systemic corticosteroid, and plasma therapy use between patients administered with these three different treatment regimens. The mean mortality age of the patients was 71 ± 14.3 years, which was substantially greater than that of the survivors (54.2 ± 15.5 years). Compared with patients administered with LPV/RTV, ICU admission and mortality rates were lower in patients administered with favipiravir. CK-MB, AST, CRP, LDH, and creatinine levels were higher, whereas lymphocyte counts were lower in patients who died. Age, AST, CRP, LDH, and neutrophil counts were higher in patients needing ICU, and eosinophil and lymphocyte counts were significantly lower. Logistic regression analysis showed that favipiravir use independently decreased mortality (p = 0.006). CONCLUSION: The use of favipiravir was more effective than LPV/RTV in reducing mortality in hospitalized patients with COVID-19. SN - 1303-6165 UR - https://www.unboundmedicine.com/medline/citation/33726482/The_comparison_of_favipiravir_and_lopinavir/ritonavir_combination_in_COVID_19_treatment_ DB - PRIME DP - Unbound Medicine ER -